ABL Bio Inc.
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
298380 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울 강남구 봉은사로 456 에이비엘바이오빌딩, 강남구
- Website:
- https://www.ablbio.com
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
ABL Bio Inc. is a clinical-stage biotechnology company that researches and develops novel antibody therapeutics, primarily focusing on bispecific antibodies. The company's core activities are concentrated in two main therapeutic areas: immuno-oncology and neurodegenerative diseases. For oncology, ABL Bio engineers bispecific antibodies and Antibody-Drug Conjugates (ADCs) designed to enhance anti-tumor immune responses and overcome resistance to existing treatments. In the neurodegenerative field, it utilizes a proprietary platform that enhances the penetration of the blood-brain barrier (BBB) to deliver therapeutics to the central nervous system for diseases like Parkinson's. A pioneer in its field in South Korea, ABL Bio was the first to advance a bispecific antibody platform into clinical trials in the country.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ABL Bio Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all ABL Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ABL Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
